Key clinical trial readouts, study launches, safety data, design changes, and patient outcomes across Phase 1–3 programs in biotech, medtech, and pharma.
The gene therapy space just got a massive validation with uniQure’s AMT-130 delivering unprecedented results in Huntington’s disease. Three-year data showing approximately 75% slowdown in
The CDC’s Advisory Committee on Immunization Practices just voted unanimously to change how we think about COVID vaccination. Instead of universal booster recommendations, they’re now
The FDA just delivered hope to families dealing with one of childhood’s most challenging rare diseases. In a groundbreaking decision, the agency has expanded access
Microbiome subsidiary faces workforce reduction following ulcerative colitis study setback, highlighting development risks in emerging therapeutic area Vedanta Biosciences, PureTech Health’s microbiome-focused subsidiary, announced workforce
Allogeneic CAR-T leader advances multiple trials with $302.6M cash position, diversifying beyond oncology into autoimmune applications Allogene Therapeutics reported strong financial positioning with $302.6 million
Neurodegeneration specialist achieves over 50% enrollment in Phase 1b PRECISE-AD trial ProMIS Neurosciences announced significant progress in its 128-patient Phase 1b PRECISE-AD trial for Alzheimer’s
Cancer therapeutics company extends MIRACLE trial footprint with $7.6M cash runway through Q4 2025 Moleculin Biotech reported $7.6 million in cash on hand, expected to
Canadian biotech advances RESOLVE Phase 2b trial for gastrointestinal indications with topline data expected H2 2026 Eupraxia Pharmaceuticals announced Q2 results and achieved a significant
First-ever Phase 3 study in HPV16-positive head and neck cancer demonstrates strong enrollment progress PDS Biotech reported Q2 results alongside significant progress in its groundbreaking
Melanoma vaccine combination shows numerical benefit but misses primary endpoint, shares plummet 34% IO Biotech’s Phase 3 trial evaluating its IO102/IO103 therapeutic cancer vaccine (Cylembio)
